• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 12, 2016

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Exposure to a sequence of rationally designed antigens could speed the development of broadly neutralizing antibodies to HIV in one strain of engineered mice, while a different strain could be used to rapidly test HIV vaccination strategies. Read More

In the clinic

Vaccinex Inc., of Rochester, N.Y., said a pre-planned interim analysis of the six-month, double-blind portion of the phase II SIGNAL trial was completed, with no safety signals identified that warranted stopping or modifying the study. Read More

Other news to note

Hologic Inc., of Marlborough, Mass., said the FDA expanded the emergency use authorization for the company's Aptima Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens). Read More

Financings

Diamedica Inc., of Winnipeg, Manitoba, closed the second tranche of a nonbrokered private placement with an investment of $3 million by Hermed Capital Healthcare Fund to secure 15 million common shares priced at 20 cents apiece. Proceeds will be used to advance Diamedica's R&D programs, including an upcoming trial of DM199, a purified form of the kallikrein known as KLK1, and for other corporate purposes. Read More

Regulatory front

The Centers for Medicare & Medicaid Services finalized a rule to establish consistent emergency preparedness requirements for health care providers participating in Medicare and Medicaid, increase patient safety during emergencies and establish a more coordinated response to natural and man-made disasters. Read More

WashU, pharma partners seek more tau intel from AD consortium

Long-time Alzheimer's disease researchers at Washington University School of Medicine in St. Louis (WashU) are partnering with three biopharmas – Abbvie Inc., Biogen Inc. and Eli Lilly and Co. – in a two-year program to investigate the buildup and clearance of tau protein in the brains of patients with the disease. Read More

Lexicon's Sanofi-backed diabetes candidate hits endpoint in phase III

Top-line results showing that type 1 diabetics treated with the dual SGLT inhibitor sotagliflozin achieved statistically significant reductions in A1C at 24 weeks in a pivotal phase III trial drew fresh enthusiasm for Lexicon Pharmaceuticals Inc. Friday, pushing shares 16.6 percent higher and encouraging partner Sanofi SA. Read More

Inflazome closes $17M series A to develop inflammasome inhibitors

DUBLIN – Newly formed startup Inflazome Ltd. has secured up to $17 million in series A funding to take forward a series of small-molecule inhibitors of the NLRP3 inflammasome, which is implicated in a wide range of chronic conditions with an underlying inflammatory component. Read More

Promising new antibiotic, derivatives, synthesized

HONG KONG – Scientists at the University of Hong Kong (HKU) have successfully synthesized teixobactin, a recently discovered antibiotic that is considered to be a breakthrough in antibacterial drug research. Read More

Biopharma sector needs to try harder to get a passing grade

The summer is over and industry executives and investors alike will be getting back to work in earnest for the final four months push until the end of the year. Both groups will be hoping for a much better period going forward. By all metrics the sector has struggled to build any sustained momentum that provides any confidence that it will close its books on 2016 in positive territory. What can we expect – more of the same, or a sudden resurgence in fortunes for the sector? Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Circode executives

    Circode applies circRNA to heart disease drug R&D, in vivo CAR T

    BioWorld
    Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Merger-arrows-black-white.png

    BD’s biosciences & diagnostics unit in $17.5B merger with Waters

    BioWorld MedTech
    Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe